The general meeting of shareholders of SIX has elected Dr Shannon Thyme Klinger, Dr Jürg Bühlmann and Stefan Helfenstein as new members of the Board of Directors. They are replacing Dr Barbara Kessler, Hermann Wirz and Dr Philipp Halbherr, who did not stand for re-election.
At the general meeting of shareholders of SIX on 20 May 2016, the following were newly elected to the Board of Directors at SIX: Dr Shannon Thyme Klinger, Chief Ethics and Compliance Officer and Head of Litigation at Novartis, as well as Stefan Helfenstein, Head of Group Accounting & Reporting at Nestlé AG, as issuer representatives, alongside Dr Jürg Bühlmann, member of the Executive Board at Zürcher Kantonalbank, as a representative of the cantonal banks. The three new members will be ideal additions to the Board of Directors at SIX thanks to their broad-based, international experience and their outstanding connections.
At the same time, the following three members of the Board of Directors did not stand for re-election: Dr Philipp Halbherr, Hermann Wirz and Dr Barbara Kessler. Dr Philipp Halbherr has represented the cantonal banks on the Board of Directors of SIX since its foundation in 2008. Hermann Wirz of Nestlé SA has been a member of the Board of Directors of SIX since 2009. Dr Barbara Kessler of Novartis International AG has been a member of the Board of Directors of SIX since 2011. The Board of Directors would like to extend its heartfelt thanks to Dr Kessler, Dr Halbherr and Mr Wirz for their longstanding commitment and their work, which has contributed to the successful strategic orientation of SIX.
Dr Shannon Thyme Klinger has been Chief Ethics and Compliance Officer and Head of Litigation at Novartis since 2016. Dr Thyme Klinger obtained her doctorate in law at the University of North Carolina in Chapel Hill (USA) and was awarded a Bachelor's degree in psychology at the University of Notre Dame (USA). She joined Novartis in 2011 as General Counsel for North America at Sandoz in the US. She became Global Head of Legal and General Counsel at Sandoz International GmbH in Germany in 2012. Dr Thyme Klinger previously held high-level legal positions at Mayer Brown LLP, Solvay Pharmaceuticals and Barr Laboratories (all in the US). Prior to this, she was a partner at Alston & Bird LLP in the US. Dr Thyme Klinger has been elected as an issuer representative and succeeds Dr Barbara Kessler on the Board of Directors at SIX.
Stefan Helfenstein has been Head of Group Accounting & Reporting at Nestlé since 2013. Mr Helfenstein studied business management at the University of St. Gallen (HSG). He has many years of practice and leadership experience in management accounting at companies with international operations, performing roles including Head of Finance & Control at Néstle Greater China Region or as Finance Controller at Shanghai Fuller Foods. Stefan Helfenstein has been elected as an issuer representative and succeeds Hermann Wirz on the Board of Directors at SIX.